Mental health visits at LifeStance reached 2.7 million in a quarter, up 17%.
LifeStance Health Group reported Q3 2026 revenue of $455.9 million, up 25% YoY, with visits reaching 2.7 million, a 17% increase. Net income rose to $22.4 million from $1.1 million, and adjusted EBITDA grew 70% to $68.4 million. The company raised full-year revenue guidance to $1.741-$1.761 billion and adjusted EBITDA to $242-$250 million.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to trigger buying interest, especially from investors focused on high‑growth health‑care niches.
Market read
First‑report earnings and guidance raise for a growth‑stage health‑care company; high relevance for traders.
What to watch
Potential reimbursement pressure or regulatory changes could offset growth.
Background
LifeStance Health is a Nasdaq‑listed provider of outpatient mental‑health services, reporting its Q3 2026 earnings and outlook.
Ticker impact
LifeStance Health reported Q3 2026 results with revenue up 25% to $455.9M and raised full‑year revenue guidance to $1.741‑$1.761B.
likely upward pressure as investors price in higher revenue and earnings outlook
Quarterly beat and upward guidance are fresh primary information that typically drive a price rally.
Market effects
Positive signal for mental‑health services and outpatient care providers.
U.S. healthcare sector may see modest lift.
Limited to U.S. listed health‑care stocks.
Counterpoint
If the market has already priced in rapid growth, the guidance raise may be already baked in.
Key entities
- companyLifeStance Health Group, Inc.
Nasdaq‑listed mental‑health services provider.
